Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes Tiziano Barbui , Alessandra Carobbio , Valerio De Stefano , Alberto Alvarez-Larran , Arianna Ghirardi , Greta Carioli , Francesca Fenili , Elena Rossi , Fabio Ciceri , Massimiliano Bonifacio , Alessandra Iurlo , Francesca Palandri , Giulia Benevolo , Fabrizio Pane , Alessandra Ricco , Giuseppe Carli , Marianna Caramella , Davide Rapezzi , Caterina Musolino , Sergio Siragusa , Elisa Rumi , Andrea Patriarca , Nicola Cascavilla , Barbara Mora , Emma Cacciola , Laura Calabresi , Giuseppe Gaetano Loscocco , Paola Guglielmelli , Francesca Gesullo , Silvia Betti , Francesco Ramundo , Francesca Lunghi , Luigi Scaffidi , Cristina Bucelli , Daniele Cattaneo , Nicola Vianelli , Marta Bellini , Maria Chiara Finazzi , Gianni Tognoni , Alessandro Rambaldi , Alessandro Maria Vannucchi Annals of Hematology（2023）
摘要
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 µg every 2 weeks for 2 years was more effective than the standard treatment of therapeutic phlebotomy in maintaining target hematocrit (HCT) (< 45
更多 查看译文
关键词
Polycythemia vera, Low-risk, Ropeginterferon alfa-2b, Phlebotomy
AI 理解论文
溯源树
样例
